Key regions: United Kingdom, Canada, Japan, Europe, China
The Dermatological Drugs market in Austria has been experiencing steady growth in recent years.
Customer preferences: Austrian consumers are increasingly concerned about their skin health and are willing to invest in high-quality dermatological drugs. They are particularly interested in products that address common skin conditions such as acne, eczema, and psoriasis. Consumers in Austria also tend to prefer natural and organic products, which has led to an increase in demand for plant-based and herbal remedies.
Trends in the market: One of the key trends in the Austrian Dermatological Drugs market is the rising demand for prescription drugs. This can be attributed to the country's aging population, which has resulted in an increase in chronic skin conditions that require medical intervention. Another trend is the growing popularity of cosmeceuticals, which are products that combine cosmetic and pharmaceutical properties. This has led to the development of a new category of dermatological drugs that are designed to improve the appearance of the skin while also providing therapeutic benefits.
Local special circumstances: The Austrian market is characterized by a high level of regulation and strict quality standards. This has led to a concentration of market share among a few large pharmaceutical companies that have the resources to navigate the complex regulatory environment. Additionally, the country's small size and relatively low population have limited the growth potential of the market, leading to intense competition among existing players.
Underlying macroeconomic factors: The Austrian economy has been performing well in recent years, with steady GDP growth and low unemployment. This has resulted in increased consumer spending on healthcare products, including dermatological drugs. However, the country's aging population and rising healthcare costs pose a challenge to the sustainability of this growth in the long term. Additionally, the ongoing COVID-19 pandemic has had a significant impact on the market, with disruptions to supply chains and changes in consumer behavior leading to fluctuations in demand.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
